Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...
This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...
Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...
A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET) ...
Discontinue CABOMETYX in patients who develop nephrotic syndrome ... Neuroendocrine Tumors. Cancers. 2022, 14(19), 4769. 7 What is a Gastrointestinal Carcinoid Tumor? ACS website.
M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs ... 1 adrenocorticotropin-producing tumor, and 1 carcinoid tumor diagnosed with diarrhea related to the pancreatic tumor. Among the 113 patients, ...
Opens in a new tab or window SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback